Zevra Therapeutics Shares Sink After Receiving Regulatory Blow

Dow Jones

Jul 24

Shares of Zevra Therapeutics tumbled after a European regulator adopted a negative opinion of the company's treatment for Niemann-Pick disease type C, a rare and life-threatening neurodegenerative disorder.

The stock fell 27% to $9.20 in premarket trading Friday. Through Thursday's close, shares are up roughly 50% year to date.

Zevra said before the bell that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a negative opinion regarding the marketing authorization application for the treatment, called arimoclomol.

Under European regulatory procedures, Zevra said it plans to request a re-examination of the CHMP opinion and submit a detailed explanation outlining the basis for the request.

"While the review did not result in the outcome we had hoped for, we are committed to investigating appropriate pathways to bring arimoclomol to patients in Europe," Chief Executive Neil McFarlane said.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

July 24, 2026 09:10 ET (13:10 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2653708790"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653708790\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653708790?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 21:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653708790","market":"hk","top_or_hot":-1,"title":"Zevra Therapeutics Shares Sink After Receiving Regulatory Blow","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/ZVRA\">Zevra Therapeutics</a> tumbled after a European regulator adopted a negative opinion of the company's treatment for Niemann-Pick disease type C, a rare and life-threatening neurodegenerative disorder. \n</p>\n<p>\n  The stock fell 27% to $9.20 in premarket trading Friday. Through Thursday's close, shares are up roughly 50% year to date. \n</p>\n<p>\n  Zevra said before the bell that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a negative opinion regarding the marketing authorization application for the treatment, called arimoclomol. \n</p>\n<p>\n  Under European regulatory procedures, Zevra said it plans to request a re-examination of the CHMP opinion and submit a detailed explanation outlining the basis for the request. \n</p>\n<p>\n  \"While the review did not result in the outcome we had hoped for, we are committed to investigating appropriate pathways to bring arimoclomol to patients in Europe,\" Chief Executive Neil McFarlane said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 24, 2026 09:10 ET (13:10 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zevra Therapeutics Shares Sink After Receiving Regulatory Blow</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZevra Therapeutics Shares Sink After Receiving Regulatory Blow\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-24 21:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/ZVRA\">Zevra Therapeutics</a> tumbled after a European regulator adopted a negative opinion of the company's treatment for Niemann-Pick disease type C, a rare and life-threatening neurodegenerative disorder. \n</p>\n<p>\n  The stock fell 27% to $9.20 in premarket trading Friday. Through Thursday's close, shares are up roughly 50% year to date. \n</p>\n<p>\n  Zevra said before the bell that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a negative opinion regarding the marketing authorization application for the treatment, called arimoclomol. \n</p>\n<p>\n  Under European regulatory procedures, Zevra said it plans to request a re-examination of the CHMP opinion and submit a detailed explanation outlining the basis for the request. \n</p>\n<p>\n  \"While the review did not result in the outcome we had hoped for, we are committed to investigating appropriate pathways to bring arimoclomol to patients in Europe,\" Chief Executive Neil McFarlane said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 24, 2026 09:10 ET (13:10 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2653708790","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653708790","pubTimestamp":1784898600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Zevra Therapeutics tumbled after a European regulator adopted a negative opinion of the company's treatment for Niemann-Pick disease type C, a rare and life-threatening neurodegenerative disorder.The stock fell 27% to $9.20 in premarket trading Friday. Through Thursday's close, shares are up roughly 50% year to date.Zevra said before the bell that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a negative opinion regarding the marketing authorization application for the treatment, called arimoclomol.Under European regulatory procedures, Zevra said it plans to request a re-examination of the CHMP opinion and submit a detailed explanation outlining the basis for the request.\"While the review did not result in the outcome we had hoped for, we are committed to investigating appropriate pathways to bring arimoclomol to patients in Europe,\" Chief Executive Neil McFarlane said.Write to Connor Hart at connor.hart@wsj.com Dow Jones Newswires","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ZVRA":"Zevra Therapeutics"},"translate_title":"Zevra Therapeutics 股价在受到监管打击后下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZVRA":1.5},"content_text":"Shares of Zevra Therapeutics tumbled after a European regulator adopted a negative opinion of the company's treatment for Niemann-Pick disease type C, a rare and life-threatening neurodegenerative disorder. \n\n\n  The stock fell 27% to $9.20 in premarket trading Friday. Through Thursday's close, shares are up roughly 50% year to date. \n\n\n  Zevra said before the bell that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a negative opinion regarding the marketing authorization application for the treatment, called arimoclomol. \n\n\n  Under European regulatory procedures, Zevra said it plans to request a re-examination of the CHMP opinion and submit a detailed explanation outlining the basis for the request. \n\n\n  \"While the review did not result in the outcome we had hoped for, we are committed to investigating appropriate pathways to bring arimoclomol to patients in Europe,\" Chief Executive Neil McFarlane said. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 24, 2026 09:10 ET (13:10 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}